# Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)

> **NCT04901325** · PHASE2 · COMPLETED · sponsor: **Oregon Health and Science University** · enrollment: 5 (actual)

## Conditions studied

- Pyoderma Gangrenosum
- Skin Diseases
- Wound Heal
- Pyoderma
- Skin Ulcer

## Interventions

- **DRUG:** Baricitinib

## Key facts

- **NCT ID:** NCT04901325
- **Lead sponsor:** Oregon Health and Science University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-03
- **Primary completion:** 2025-01-05
- **Final completion:** 2025-05-07
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2025-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04901325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04901325, "Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04901325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*